BCL-XL-targeting antibody-drug conjugates are active in preclinical models and mitigate on-mechanism toxicity of small-molecule inhibitors
靶向BCL-XL的抗体药物偶联物在临床前模型中具有活性，并能减轻小分子抑制剂的靶向毒性。
期刊:Science Advances
影响因子:11.7
doi:10.1126/sciadv.ado7120
Andrew S Judd ,Bhupinder Bawa ,Wayne R Buck ,Zhi-Fu Tao ,Yingchun Li ,Michael J Mitten ,Milan Bruncko ,Nathaniel Catron ,George Doherty ,Kenneth R Durbin ,Brian Enright ,Robin Frey ,Deanna Haasch ,Sandra Haman ,Anthony R Haight ,Tracy A Henriques ,James Holms ,Kamel Izeradjene ,Russell A Judge ,Gary J Jenkins ,Aaron Kunzer ,Joel D Leverson ,Ruth L Martin ,Diya Mitra ,Scott Mittelstadt ,Lorne Nelson ,Paul Nimmer ,Joann Palma ,Richard Peterson ,Darren C Phillips ,Sherry L Ralston ,Saul H Rosenberg ,Xiaoqiang Shen ,Xiaohong Song ,Kedar S Vaidya ,Xilu Wang ,Jin Wang ,Yu Xiao ,Haichao Zhang ,Xinxin Zhang ,Eric A Blomme ,Erwin R Boghaert ,John C Kalvass ,Andrew Phillips ,Andrew J Souers
